OBJECTIVES: Systemic arterial hypertension (SAH) is a chronic condition, and despite the large number of available antihypertensive drugs, patients with SAH who are drug-treated frequently do not obtain goal Blood Pressure (BP) levels. A combination of drugs is recommended for those cases, however, compliance is improved when agents are prescribed as fixed dose combinations rather than separate pills. A combination of bisoprolol and amlodipine once a day showed a rapid reduction of BP after 4 weeks. The aim of this paper is to perform cost-effectiveness (CE) and budget impact (BI) analyses of Concor® AM compared to amlodipine + bisoprolol as separate tablets. METHODS: A daily-cycle markov model was built considering the outcomes: days on treatment; number of events (stroke, myocardial infarction, heart failure and angina); number of full-lifetime-patients with transitory drug interruption (non-compliance); number of full-lifetime-patients with normal blood pressure and days of life. Efficacy data were obtained from literature review and unit costs were obtained from official price lists. The time horizon of the CE and BI model was 30 and 10 years, respectively. A 5% annual discount rate was applied in costs and benefits in the CE model. RESULTS: Concor® AM increased overall survival in 43 days and assured more 2,090 days on treatment, per patient, during lifetime period. Also, reduced 183 events, and allowed more 187 patients with controlled blog pressure, per 1,000 patients. Concor® AM was dominant vs. Concor + Amlodipine, resulting in financial resource saving of approximately 8.1% (BRL 5,720.72 per patient). Additionally, the use of Concor® AM in patients with SAH resulted in financial resource saving of approximately BRL 300,321,412.45, in the period from 2014 to 2025. CONCLUSIONS: Fixed-dose combinations such as Concor-AM do represent an oportunity to increase compliance and consequently health outcomes and its costs.